<DOC>
	<DOCNO>NCT01903824</DOCNO>
	<brief_summary>This single center , double-blind , placebo positive-controlled , randomize , partial 6-way cross-over study investigate pharmacodynamics pharmacokinetics CEP-26401 ( 5 , 25 , 125 μg ) follow single-dose administration healthy male female subject .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics ( PK/PD ) CEP-26401 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . The subject able give legal inform consent understand requirement study communicate investigator local spoken language . 2 . The subject willing comply study requirement ( eg , dietary , exercise , tobacco , alcohol restriction ) provide write informed consent participate study . 3 . The subject man woman , 18 50 year age , inclusive . 4 . The subject body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive . 5 . The subject skin type I IV ( light olive ) . 6 . The subject good health determine medical history , ECG , vital sign , physical examination , clinical laboratory test . 7 . Female subject childbearing potential must negative serum βhuman chorionic gonadotropin ( hCG ) test ( screen ) checkin willing able use one protocolspecified doublebarrier method birth control . 8 . The subject able complete screen process within 4 week prior study drug administration . 1 . The subject cognitive performance outside reference value screen . 2 . The subject smoke , tobacco user , currently use nicotine product . 3 . The subject know hypersensitivity donepezil , modafinil , irdabisant , one excipients , significant food drug allergy . 4 . The subject female pregnant lactating . 5 . The subject intraocular pressure great 22 mm Hg . 6 . The subject suffering , clinically significant history one following : cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) , history illness , opinion investigator , might pose additional risk subject participation study confound result study . 7 . The subject laboratory abnormality judge investigator clinically significant , measurement outside define range Other exclusion criterion apply ; please contact investigator information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Irdabisant</keyword>
	<keyword>cognitive impairment</keyword>
</DOC>